No Data
No Data
No Data
No Data
No Data
KalVista Pharmaceuticals: A Strong Buy on Strategic Growth and Promising Sebetralstat Prospects
TipRanks00:15
Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The On-demand Treatment Of Hereditary Angioedema
Kalvista Pharmaceuticals Announced Its Strategic Plans For Fiscal Year 2025, Beginning May 1, Including For Sebetralstat, The Company's Investigational Novel, Oral Plasma Kallikrein Inhibitor For The
BenzingaMay 1 18:38
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive result
KalVista PharmaceuticalsMay 1 12:00
KalVista Pharmaceuticals Welcomes New Board Member
TipRanksApr 23 05:13
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
Dow JonesApr 22 18:35
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
Dow JonesApr 22 18:30
No Data
No Data